Press Releases Year All News202020192018201720162015 Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares December 16, 2019 Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock December 11, 2019 Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock December 11, 2019 Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation December 9, 2019 Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia December 9, 2019 Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights November 12, 2019 bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy November 12, 2019 Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting November 6, 2019 Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 November 5, 2019 Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference September 27, 2019 Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 34
